These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1674947)

  • 21. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine?
    Meltzer HY; Jayathilake K
    J Clin Psychiatry; 1999; 60 Suppl 10():47-51. PubMed ID: 10340687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroleptic dosing in Hispanic and Asian Inpatients with schizophrenia.
    Collazo Y; Tam R; Sramek J; Herrera J
    Mt Sinai J Med; 1996; 63(5-6):310-3. PubMed ID: 8898533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuroleptic malignant syndrome. Case reports].
    Berardi D; Troia M; Veronesi L; Ferrari G
    Minerva Psichiatr; 1994 Dec; 35(4):199-219. PubMed ID: 7861943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of neuroleptic-resistant schizophrenic relapse.
    Kinon BJ; Kane JM; Johns C; Perovich R; Ismi M; Koreen A; Weiden P
    Psychopharmacol Bull; 1993; 29(2):309-14. PubMed ID: 7904762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S; Kornreich C; Choubani Z; Gourevitch R
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse.
    Heresco-Levy U; Greenberg D; Lerer B; Dasberg H; Brown WA
    Isr J Psychiatry Relat Sci; 1995; 32(4):268-75. PubMed ID: 8641856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor neuroleptic response in acutely exacerbated schizophrenic patients.
    Shalev A; Hermesh H; Rothberg J; Munitz H
    Acta Psychiatr Scand; 1993 Feb; 87(2):86-91. PubMed ID: 8095362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Method for evaluation of neuroleptic dosage reduction.
    Lonowski DJ; Sterling FE; Kennedy JC
    Psychol Rep; 1979 Feb; 44(1):15-20. PubMed ID: 37540
    [No Abstract]   [Full Text] [Related]  

  • 30. The neuroleptic threshold as a marker of minimum effective neuroleptic dose.
    McEvoy JP
    Compr Psychiatry; 1986; 27(4):327-35. PubMed ID: 2873960
    [No Abstract]   [Full Text] [Related]  

  • 31. Instrumental evidence that age increases motor instability in neuroleptic-treated patients.
    Caligiuri MP; Lohr JB; Jeste DV
    J Gerontol; 1991 Sep; 46(5):B197-200. PubMed ID: 1679770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A decision analysis approach to neuroleptic dosing: insights from a mathematical model.
    Mossman D
    J Clin Psychiatry; 1997 Feb; 58(2):66-73. PubMed ID: 9062375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic dose reduction in stable chronic schizophrenia.
    Tsuruta S; Nomura S; Yoshino A
    Schizophr Res; 2003 Jan; 59(1):95-6. PubMed ID: 12413649
    [No Abstract]   [Full Text] [Related]  

  • 34. Implications of increased dosage of neuroleptic medications during psychotherapy.
    Digiacomo JN; Cornfield R
    Am J Psychiatry; 1979 Jun; 136(6):824-7. PubMed ID: 35988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of a low dose neuroleptic treatment strategy.
    Miller F; Tanenbaum JH
    J Clin Psychopharmacol; 1988 Oct; 8(5):378-9. PubMed ID: 2903185
    [No Abstract]   [Full Text] [Related]  

  • 36. High dose of multiple neuroleptic treatments for schizophrenia in Japan: dose reduction and electrocardiographic changes.
    Kawai N; Yamakawa Y; Hori T; Tachikawa H; Asada T
    J Clin Psychopharmacol; 2005 Apr; 25(2):186-8. PubMed ID: 15738754
    [No Abstract]   [Full Text] [Related]  

  • 37. Low-dose neuroleptic regimens in the treatment of borderline patients.
    Brinkley JR; Beitman BD; Friedel RO
    Arch Gen Psychiatry; 1979 Mar; 36(3):319-26. PubMed ID: 33635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The quest for the correct dose.
    Glazer WM
    Behav Healthc; 2010 Sep; 30(8):38, 40. PubMed ID: 21114244
    [No Abstract]   [Full Text] [Related]  

  • 39. Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: An effect size analysis.
    Barbui C; Saraceno B
    Eur Psychiatry; 1996; 11(8):412-5. PubMed ID: 19698493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marketing policies for neuroleptic drugs.
    Kinnell HG
    Br Med J (Clin Res Ed); 1984 Nov; 289(6456):1455-6. PubMed ID: 6149787
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.